Immatics N.V. IMTX 深 沪
等待开盘 08-17 09:30:00 美东时间
9.44
-0.150
-1.56%
华盛通- 最 高9.68
- 今 开9.68
- 成交量 36.27万股
- 最 低 9.39
- 昨 收 9.59
- 总市值 12.90亿
- 52周最高 12.41
- 市盈率 静 --
- 换手率 0.27%
- 52周最低 5.05
- 委 比 -53.76%
- 总股本 1.37亿
- 历史最高 18.42
- 量 比 1.41
- 振 幅 3.02%
- 历史最低 3.30
- 每 手 1
- 风险率 1.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
<p>Immatics N.V. announced three presentations at the ESMO Congress 2026 in Madrid, Spain, focusing on its PRAME-targeted therapies. These include Phase 1b data for anzu-cel in melanoma, Phase 1 data for IMA203CD8 in solid tumors, and Phase 1b data for IMA402 bispecific across cancers. The presentations highlight the company's broad PRAME franchise and its potential across various tumor types. Full abstracts will be available on the ESMO website ...
07-17 14:25
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
Immatics N.V. announced updated Phase 1 data for its IMA203CD8 PRAME TCR T-cell therapy, showing significant anti-tumor activity in platinum-resistant ovarian cancer and uterine cancer with a 63% objective response rate (ORR) and 50% confirmed ORR (cORR), including four complete responses. In heavily pretreated patients with synovial sarcoma, the therapy demonstrated a 67% ORR and 64% cORR, with responses lasting up to ~3 years. IMA203CD8 exhibit...
05-30 12:00
Immatics Q1 EPS $(0.50) Misses $(0.42) Estimate, Sales $8.914M Miss $14.590M Estimate
Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.42) by 19.05 percent. This is a 42.86 percent decrease over losses of $(0.35) per share from the
05-12 19:29
TD Cowen Initiates Coverage On Immatics with Buy Rating
TD Cowen analyst Nicholas Lorusso initiates coverage on Immatics (NASDAQ:IMTX) with a Buy rating.
04-28 23:59
Immatics Announces Its Abstract Regarding Pediatric Participant Treatment With PRAME-Directed Cell Therapy Using Its PRAME T-Cell Receptor Accpected For Poster Presentation At American Association For Cancer Research Annual Meeting 2026
Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced that an abstract
04-18 03:08
Immatics Earnings Report: Q4 Overview
The Q4 earnings report for Immatics (NASDAQ:IMTX) was released on Thursday, Mar...
03-05 20:14
Immatics Q4 EPS $(0.34) Beats $(0.48) Estimate, Sales $23.005M Beat $12.180M Estimate
Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.48) by 29.17 percent. This is a 170.83 percent decrease over earnings of $0.48 per share from the
03-05 20:12
Immatics Unveils IMA203CD8 Phase 1a Findings Demonstrating Durable Responses And Tumor-Agnostic Potential In PRAME-Expressing Cancers
IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor activity in advanced
2025-12-11 20:11
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Praxis Precision Medicine (NASDAQ:PRAX) shares moved upwards by 33.6% ...
2025-12-06 01:05
